<DOC>
	<DOC>NCT03000530</DOC>
	<brief_summary>This is a two-part (open-label followed by double-blind) study evaluating the safety, tolerability, pharmacokinetics, and efficacy of SAGE-217 in up to 62 subjects diagnosed with moderate to severe Major Depressive Disorder.</brief_summary>
	<brief_title>A Study to Evaluate SAGE-217 in Subjects With Moderate to Severe Major Depressive Disorder</brief_title>
	<detailed_description>Part A of the study is an open-label design with dosing of SAGE-217 for 14 days. Part B of the study is a randomized, double-blind, parallel-group, placebo-controlled design. Eligible subjects will be randomized to SAGE-217 or placebo for 14 days.</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<criteria>Subject has a diagnosis of Major Depressive Disorder that has been present for at least a 4week period as diagnosed by Structured Clinical Interview for DSMIV Axis I Disorders (SCIDI) Subject has a history of suicide attempt Subject has a history of treatmentresistant depression, defined as persistent depressive symptoms despite treatment with adequate doses of antidepressants from two different classes for an adequate amount of time Active psychosis Medical history of seizures Medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Depression</keyword>
</DOC>